603367 辰欣药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.8088.7169.4286.7386.781
总资产报酬率 ROA (%)3.0206.8357.3675.3115.334
投入资产回报率 ROIC (%)3.6108.2228.8786.3996.331

边际利润分析
销售毛利率 (%)56.16256.57358.78855.99555.463
营业利润率 (%)14.75714.36713.2808.9668.841
息税前利润/营业总收入 (%)14.04913.64512.5988.3208.646
净利润/营业总收入 (%)13.29412.93311.7758.6648.827

收益指标分析
经营活动净收益/利润总额(%)96.08286.51199.96895.16173.120
价值变动净收益/利润总额(%)21.65112.6505.6634.24919.761
营业外收支净额/利润总额(%)-0.1110.6470.5500.4390.509

偿债能力分析
流动比率 (X)3.6493.3333.6283.7013.400
速动比率 (X)3.0952.7883.1113.2492.912
资产负债率 (%)19.63620.74321.41521.41220.556
带息债务/全部投入资本 (%)3.4424.4584.5674.5272.434
股东权益/带息债务 (%)2,764.2582,118.0932,063.5452,078.6953,938.352
股东权益/负债合计 (%)406.578379.711364.479365.406386.412
利息保障倍数 (X)-20.306-16.725-16.697-12.136-36.002

营运能力分析
应收账款周转天数 (天)68.32161.93258.75854.20147.925
存货周转天数 (天)187.113158.092126.130118.211124.666